ArticleClinical and experimental pharmacology & physiology2019
High expression of DLG3 is associated with decreased survival from breast cancer.
Article in Clinical and experimental pharmacology & physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- A cancer neuroscience-related gene model for prognosis prediction and immunotherapy response evaluation in breast cancer.Discover oncology · 2026Article
- Determining a Stability Prognostic Panel for 636 Patients With Melanoma Using a Machine Learning Computational Framework.Experimental dermatology · 2025Article
- Molecular characterization and prognostic modeling associated with M2-like tumor-associated macrophages in breast cancer: revealing the immunosuppressive role of DLG3.Frontiers in immunology · 2025Article
- KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid accumulation in pancreatic ductal adenocarcinoma.Cell death discovery · 2024Article
- HIPPO signaling-related signature for predicting prognosis and therapeutic response in gastric cancer.Frontiers in pharmacology · 2022Article
- The loss of DLG2 isoform 7/8, but not isoform 2, is critical in advanced staged neuroblastoma.Cancer cell international · 2021Article
- Identification of markers associated with brain metastasis from breast cancer through bioinformatics analysis and verification in clinical samples.Gland surgery · 2021Article
- Cytochrome b561 Serves as a Potential Prognostic Biomarker and Target for Breast Cancer.International journal of general medicine · 2021Article
- Characterizing the Binding Sites for GK Domain of DLG1 and DLG4 via Molecular Dynamics Simulation.Frontiers in molecular biosciences · 2020Article
- High expression of DLG3 is associated with decreased survival from breast cancer.Clinical and experimental pharmacology & physiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormal expression or activity of proteins that regulate cell polarity can contribute to tumour progression. Discs large homolog (DLG) proteins play crucial roles in the maintenance of cell polarity and tissue morphogenesis. Previous studies of breast cancer patients showed that DLG3 had greater expression in the cancerous tissues than non-cancerous tissues, but the relationship between DLG3 expression and breast cancer progression and prognosis is not clear. Here, we investigated the association of DLG3 expression with breast cancer progression and prognosis using data on clinicopathological parameters from The Cancer Genome Atlas (TCGA) database, with different clinicopathological parameters using ualcan and LinkedOmics, and with different stages and subtypes using immunohistochemical staining. The results indicated greater DLG3 expression in cancerous breast tissues than normal breast tissues and in luminal and Her2+ subtypes than in the triple-negative subtype. DLG3 expression also had a positive correlation with pathologic stage and decreased survival rate. Our data suggest that DLG3 should be considered as a new diagnostic and prognostic biomarker for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.